Suven Participates at Biotech Showcase 2009

HYDERABAD, India (January 13, 2009)--SUVEN Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets for CNS disorders with unmet medical need and high market potential, today announced that it is participating at Biotech Showcase 2009 scheduled to be held at San Francisco, USA on January 14th 2009.

Biotech Showcase brings together life science industry leaders and dealmakers providing with an unparalleled opportunity to create new value generating partnerships.

Mr. Venkat Jasti CEO of Suven Life Sciences is scheduled to discuss the company’s business strategy, corporate overview and to present the data on their lead Phase 1 clinical candidate SUVN-502 for cognition in Alzheimer’s and Schizophrenia at the Biotech Showcase 2009, San Francisco, USA where the world’s top notch investment professionals will present along with the most innovative companies who present themselves to a targeted audience of decision makers.

Suven Life Sciences has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia, and depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.

Posted: January 2009

View comments

Hide
(web5)